Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Articles

GlaxoSmithKline and Daiichi Sankyo have formed a joint venture that they claim will create the biggest vaccines company in Japan. The joint venture will seek to improve access to vaccinations in the Asian nation as well as introduce new vaccines.

GSK and Daiichi Sankyo Launch Vaccine Venture in Japan

The divide between innovation and conflict of interest in medical research is not so clear.

Defining Conflict of Interest

Angie Drakulich was editorial director of Pharmaceutical Technology.

Has the long-awaited guidance answered all of the industry's questions?

FDA Guides the Way to Biosimilars in the US

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

The article examines some recent developments for this process step and for continuous manufacturing overall.

Advancing Unit Operations for Continuous Processing in Solid-Dosage Manufacturing

Tim Freeman is Managing Director of powder characterization company Freeman Technology for whom he has worked since the late 1990s. He was instrumental in the original design and continuing development of the FT4 Powder RheometerÂ® and through his work with various professional bodies, and involvement in industry initiatives, is an established contributor to wider developments in powder processing.Tim has a degree in Mechatronics from the University of Sussex in the UK. He is a mentor on a number of project groups for the Engineering Research Center for Structured Organic Particulate Systems in the US and a frequent contributor to industry conferences in the area of powder characterisation and processing. A past Chair of the American Association of Pharmaceutical Scientists (AAPS) Process Analytical Technology Focus Group Tim is a member of the Editorial Advisory Board of Pharmaceutical Technology and features on the Industry Expert Panel in European Pharmaceutical Review magazine. Tim is also a committee member of the Particle Technology Special Interest Group at the Institute of Chemical Engineers, Vice-Chair of the D18.24 sub-committee on the Characterization and Handling of Powders and Bulk Solids at ASTM and a member of the United States Pharmacopeial (USP) General Chapters Physical Analysis Expert Committee (GC-PA EC).

This article considers the different conditions to which the powder is subjected in the tableting process, and discusses which powder properties should be measured to accurately reflect likely powder behavior in the process.

Powder Testing Techniques for Tablet Manufacture

Taste-masking is an important consideration to ensure patient compliance.

Advances in Taste-masking

Experts in solid dosage discuss the formulation and manufacture of multilayer tablets.

Multilayer Tablets: Key Challenges and Trends

FDA answers key questions about the October 2011 guidance on using physical–chemical identifiers in solid oral dosage products to help prevent and avoid counterfeiting.

Physical-Chemical Identifiers: A Q&A with FDA on the Final Guidance

The pharma industry has reached the long-dreaded patent cliff, but for copycat products, business is booming.

News: Market Boom for Generics

JHS Secures Four Sterile Parenteral Products Manufacturing Contracts; Samsung Biologics, Biogen Idec Establish Biosimilars Joint Venture; and More.

Week of Feb. 27, 2012: JHS Secures Four Sterile Parenteral Products Manufacturing Contracts; Samsung Biologics, Biogen Idec Establish Biosimilars Joint Venture; and More